The major obstacle to cure infections with human immunodeficiency virus (HIV-1) is integrated proviral genomes, which are not eliminated by antiretroviral therapies (ART). Treatment approaches with latency-reversing agents (LRAs) aim at inducing provirus expression to tag latently-infected cells for clearance through viral cytopathic effects or cytotoxic T cell (CTL) responses. However, the currently tested LRAs reveal evident drawbacks as gene expression is globally induced and viral outgrowth is insecure. Here, we present transcription activator-like effector (TALE) proteins as potent tools to activate HIV-1 specifically. The large variety of circulating HIV-1 strains and, accordingly, integrated proviruses was addressed by the programmable DNA-specificity of TALEs. Using customized engineered TALEs, a substantial transcription activation and viral outgrowth was achieved with cells obtained from different HIV-1 patients. Our data suggest that TALEs may be useful tools in future strategies aimed at removing HIV-1 reservoirs.
Introduction
ART has been a major accomplishment in HIV/AIDS treatment as it enables a prolonged suppression of HIV replication resulting in a decreased morbidity of HIV-1 infected patients (Van Lint et al., 2013; Geeraert et al., 2008) . However, even intensified ART treatment cannot eradicate HIV-1, and viremia frequently rebounds upon ART cessation (Finzi et al., 1997; Wong et al., 1997) . New strategies towards an HIV-1 cure aim at directly targeting the integrated HIV-1 proviruses in cellular reservoirs, such as resting memory CD4 þ T cells, where viral gene expression is episodic or silenced due to epigenetic, transcriptional or post-transcriptional blocks (Choudhary and Margolis, 2011; Katlama et al., 2013; Xing and Siliciano, 2013; Williams and Greene, 2007) . A promising approach to overcome HIV-1 latency while viral propagation is inhibited by ART, is to induce viral gene expression to designate latently-infected cells for elimination by host immune mechanisms or by viral cytopathic effects ('shock and kill' strategy) (Geeraert et al., 2008) . Along this line, mechanistically distinct LRAs were characterized that are capable to induce HIV-1 transcription in resting CD4 þ T cells (Choudhary and Margolis, 2011; Katlama et al., 2013; Xing and Siliciano, 2013) . One group of LRAs is histone deacetylase inhibitors (HDACis), which stimulate gene expression by histone acetylation-mediated chromatin remodeling and transcriptional start site (TSS) release (Shirakawa et al., 2013) . However, HDACis, such as suberoylanilide hydroxamic acid (SAHA, Vorinostat), bear drawbacks that relate to the global up-regulation of cellular gene expression, which causes unpredictable side effects and a considerable toxicity. Moreover, Vorinostat appears to fail to stimulate constant viral outgrowth, which is an important prerequisite for subsequent CTL-mediated virus elimination (Blazkova et al., 2012; Bullen et al., 2014; Cillo et al., 2014) . Other examples of LRAs are Disulfiram and protein kinase C (PKC) pathway agonists, which increase HIV-1 transcription by activating cellular transcription factors that operate on the proviral 5'LTR (e.g. NF-κB, NFAT, AP-1, SP1). However, as with HDACis, this stimulation is not restricted to HIV-1 infected cells (Van Lint et al., 2013; Choudhary and Margolis, 2011; Katlama et al., 2013; Xing Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/yviro and Siliciano, 2013; Blazkova et al., 2012; Bullen et al., 2014; Cillo et al., 2014) , and a successful treatment of different HIV-1 subtypes is impeded by sequence variations in the transcription factor binding sites (de Arellano et al., 2010) . Clinical trials indeed revealed no indications that LRAs may reduce latent HIV-1 reservoirs in infected individuals (Van Lint et al., 2013; Katlama et al., 2013; Shirakawa et al., 2013; Cillo et al., 2014) . This situation highlights the need for specific and effective means to reverse latency. These should (i) induce HIV-1 transcription in the absence of global cell activation and toxicity and (ii) induce viral outgrowth to label infected cells for elimination by the immune system. Addressing these criteria, we followed a new strategy applying HIV-1-specific transcription activator-like effectors (TALEs). TALEs were originally characterized in plant-pathogenic bacteria that translocate these proteins into host cells to reprogram gene expression. TALEs contain a unique central DNA-binding domain composed of nearly identical, tandem 34 aa repeats. Each repeat binds to one DNA base pair, and a repeat-variable di-residue (RVD) specifies which base is recognized (Boch et al., 2009; Moscou and Bogdanove, 2009) . Accordingly, the DNA binding specificity of TALEs can easily be engineered by choosing the number and order of repeats. 'Designer TALEs' were shown to enable the specific induction of human gene expression (Zhang et al., 2011; Geissler et al., 2011; Renner et al., 2014) .
Results
13 TALEs (TALEs 1-13) were generated to target the HIV-1 promoter region in the proviral 5'LTR (nucleotide position À172 to À16), which also contains the binding sites of natural transcription factors. The TALEs consisted of 17.5 repeats and recognized overlapping stretches of 19 nucleotides in the 5'LTR, respectively ( Fig. 1) . A non-HIV-targeting TALE (TALE 14) served as a negative control. To support efficient transcriptional activation in human cells, all TALEs were generated with the transcription activation domain of herpes simplex virus VP16, and all genes were codon-optimized. Codonoptimization was essential to express the TALEs at high concentrations in human cells and to achieve a high efficacy of transcription activation ( Supplementary Fig. 1 
) (Figs. 1 and 2).
To test TALEs 1-13 on the activation of an authentic HIV-1 provirus, we first applied the human T cell line 8E5 that persistently produces non-infectious HIV-1 particles at low titer (Folks et al., 1986) . Each 8E5 cell contains a single proviral DNA copy integrated at a defined genomic locus. Accordingly, all TALEs were tested in an identical chromosomal background. Expression of the TALE proteins in 8E5 cells was performed either by a murine retroviral vector or by a HIV vector system (Fig. 2) , of which both strategies yielded analogous data. TALE 14 or the green fluorescent protein (GFP) was expressed as negative controls. Measurements of the intracellular HIV-1 RNA levels by qRT-PCR and primers recognizing the 5 0 -terminal gag-coding region revealed a distinct pattern of transcriptional induction in the 8E5 cells that expressed TALEs 1-13 (see Fig. 1 and Fig. 3A ).
While TALEs 10-13, which targeted the SP1 binding sites or the TATA box, had no effect (comparable to the negative controls), the HIV-1 transcription was significantly stimulated in cells that contained TALEs 1-9. TALEs 5 and 6, which targeted the region between the LEF-1 and NF-κB binding sites induced the intracellular level of HIV-1 RNA up to 65-fold. In comparison, treatment of the cells with a non-cytotoxic concentration of 350 nM Vorinostat leads to an about 5-fold increase in intracellular HIV-1 RNA synthesis, which is consistent with earlier reports (Archin et al. (2012) and Fig. 3A ). qRT-PCR measurements with primers covering the genomic 3'-terminal nef-coding region revealed a 10-fold increase in HIV-1 RNA levels by comparing cells that expressed TALEs 5 and 14 ( Fig. 1 and Fig. 3B ). This indicates that TALEs induce the transcription of full-length HIV-1 RNA, which is important for successful genome packaging. To directly determine the amount of viral RNA that is released from infected cells, we analyzed cell-free culture supernatants by qRT-PCR detecting the nef-region. By comparing supernatants from TALE 5-expressing and TALE 14-expressing cells, we detected an approximately 30-fold increase in the number of released HIV-1 RNA molecules in the TALE 5-expressing cells ( Fig. 3C ). That is, 3 Â 10 5 8E5 control cells (expressing TALE 14 or GFP), produced an average titer of 1.4 Â 10 5 HIV-1 RNA molecules per ml culture medium (corresponding to 0.7 Â 10 5 virions per ml; one virion contains two RNA molecules). The same number of TALE 5induced 8E5 cells produced about 4.2 Â 10 6 RNAs (2.1 Â 10 6 virions) per ml culture supernatant. Treatment with Vorinostat led to an approximately 3-fold increase in the number of full-length HIV-1 RNA molecules in the 8E5 supernatants ( Fig. 3C ).
To further evaluate the accessibility of the promoter region between the LEF-1 and NF-κB, which was earlier termed as HS2 region (Van Lint et al., 1996) , we tested two additional TALEs (15 and 16) that targeted the complementary DNA binding region of TALE 5 and TALE 8, respectively. TALEs 15 and 16 induced HIV-1 transcription at similar efficacy as TALEs 5 and 8 ( Fig. 4 ) confirming that both strands of the proviral DNA are freely approachable by TALEs. Moreover, these data demonstrated that successful assembly of the transcription complex was defined by the TALE-binding position and not by the orientation or distance of the VP16 activation domain to the HIV promoter's TATA box.
In the following studies we investigated the most potent TALE 5 concerning its potential to enforce HIV-1 transcription and viral outgrowth in infected primary cells. Peripheral blood mononuclear cells (PBMCs) were isolated from two HIV-1 infected patients (P1, P2), who achieved sustained control of viral replication during cART (o50 RNA genome copies/ml). Considering the presence of SNPs (single nucleotide polymorphisms) in circulating HIV-1 strains, the TALE 5 binding site within the HIV-1 5'LTR was amplified, cloned and sequenced (Fig. 5 ). All analyzed clones obtained from P1 and P2 were found to contain a main SNP of a G to T exchange at position -111 in comparison to the provirus strain (NL4-3) contained in 8E5. For that reason, we generated a patient-adapted, 'customized' TALE (TALE P1/2) that optimally matched with the HIV-1 promoter region of both patients (Fig. 5 ). Following lentiviral delivery and expression of TALE P1/2 and TALE 14 in 1 Â 10 6 CD8þ T cell depleted PBMCs of P1 and P2, respectively, the cell's vitality was confirmed to be unaffected, and the intracellular HIV-1 levels were analyzed by qRT-PCR at day 6 post-infection. (TALE 14; HIV-1 RNA level set to 1). TALE-mediated transcription induction was compared to that obtained by Vorinostat (VOR) or DMSO (-) treatment. (C) Extracellular HIV-1 RNA levels in the supernatants of 8E5 that expressed TALE 5, TALE 14 or GFP or that were treated with VOR. qRT-PCR data with primers recognizing the nef-coding region are presented as fold change relative to the controls (TALE 14 or (-); HIV-1 RNA level set to 1). Error bars indicate standard deviations of three independent experiments, (**) Pr 0.01, (***) P r0.001. Note that in each case, we applied the very same pools of cells for the inoculation with lentiviruses that expressed either TALE P1/ P2 or the control TALE 14. Furthermore, by testing for activation markers and HIV-1 release, the cells were controlled with respect to HIV-1 activation, and it was demonstrated that the analyzed amounts of PBMCs indeed contained integrated HIV-1 (Fig. 6 ). As shown in Fig. 7A , by detecting the gag-coding region in cells that expressed TALE P1/2, a significant increase of HIV-1 transcription of 3 to 7-fold was observed in comparison to the TALE 14 negative control. Interestingly, when we measured the levels of the HIV-1 protein p24 in the cell-free supernatant at days 6 and 10 by a quantitative p24 antigen ELISA, these data indicated a substantial viral outgrowth. That is, with TALE P1/2, the signal was elevated by 3-to 10-fold versus the control with TALE 14 ( Fig. 7B and C) . This increase in the expression of viral protein by TALE P1/2 essentially correlated with increased levels of full-length viral RNA molecules in the PBMC supernatants during a time-course experiment of several days: i.e., at day 10, P1 showed a ca. 100-fold increase, P2 showed a ca. 6-fold increase (Fig. 7D and E) .
These data indicated that TALEs binding to specific sites of the HIV-1 promoter are capable to specifically and efficiently induce HIV-1 transcription and viral outgrowth in HIV-1 patient-derived primary cells.
Discussion
The success of future HIV-1 eradication strategies will critically depend on the combination of various technical approaches. These may include therapeutic vaccination strategies and gene therapies, for example to inactivate the CCR5 receptor or to excise the integrated proviral DNA (Shan et al., 2012; Perez et al., 2008; Sarkar et al., 2007; Mitsuyasu et al., 2009; van Lunzen et al., 2007) . The currently most advanced approaches to eliminate latently-infected cell reservoirs strive to enhance viral gene expression by small 6 . Tests of activated patient PBMCs for activation markers and HIV-1 release. CD8-depleted cells from the respective patients were stimulated with IL-2 alone or with IL-2þ PHA-Pþ PMA. At days 2, 4 and 6, the culture supernatants were analyzed for the presence of the indicated cell subsets by staining with monoclonal antibodies and FACS analysis (Left panels) or for virus load (Right panels). molecular weight drugs (e.g. Vorinostat) to tag these cells for clearance by the host's immune system (Van Lint et al., 2013; Choudhary and Margolis, 2011; Katlama et al., 2013; Xing and Siliciano, 2013 ). Unfortunately, currently tested latency reversing drugs frequently fail to induce HIV antigen production in latent reservoirs (Blazkova et al., 2012; Bullen et al., 2014) and, furthermore, may also increase the susceptibility of uninfected cells to HIV (Lucera et al., 2014) . Moreover, it has been demonstrated that various LRAs negatively interfere with CTL function (Jones et al., 2014) and that a population of replication-competent proviruses exists that cannot be induced with current LRAs (Ho et al., 2013) . Particularly the latter finding suggests that the size of the latent reservoir is up to 60-fold greater than previously believed, thereby significantly raising the barrier to cure (Ho et al., 2013) .
Here, we provide the proof of principle that 'designer' transcription factors are capable to specifically and significantly increase HIV-1 gene expression in provirus-containing cells. Although TALE delivery via lentiviral vectors required cellular activation of target cells, careful control of our experiments demonstrated significant TALE-specific effects on transcriptional activation of proviral DNAs. Thus, with the (non-stimulated) 8E5 T cell line, the HIV-specific TALEs induced provirus transcription and secretion of viral RNA into the supernatant, i.e., via the expression of these TALEs, low HIV producing cells were modified into high producing cells. Comparable data were obtained with the patientderived primary cells: also here, we demonstrated a TALEdependent significant increase in viral transcription and outgrowth in addition to the PHA/PMA stimulation that was necessary to achieve an efficient transduction of the cells by the TALEexpressing lentiviruses. Interestingly, with both types of cells, we observed an efficient TALE-driven transcription when the respective TALE targeted the HS2 region of the HIV-1 LTR enhancer ( Fig. 1; Fig. 3 ). While in other HIV provirus-containing cell types HS2 was found to be hypersensitive to nucleases (Van Lint et al., 1996) , these results suggest that the HS2 HIV-1 promoter region may be generally accessible for a TALE-mediated enforcement of HIV gene expression. It is therefore expected that engineered TALEs may also be highly useful for specific activation of competent reservoir proviruses that are otherwise not stimulated by initial drug-based approaches (Ho et al., 2013) .
In particular, TALEs may offer several key advantages in potential anti-HIV future applications. (i) TALE activity supports the highly increased production of viral RNA, proteins and apparently virions, which is a major prerequisite for effective clearance of latent reservoirs. (ii) TALEs induce HIV-1 gene expression in a highly specific manner and, as demonstrated, the TALE proteins may be customized to individual viruses. Hence, in combination with next-generation sequencing to determine 5'LTR variations and/or other proviral mutations, patient-adapted TALEs may be designed. Along the same line, the problem that a large majority of proviruses appears to be not induced by LRAs such as HDACis (Blazkova et al., 2012; Bullen et al., 2014; Cillo et al., 2014) may be addressed by specifically designed TALEs.
All applied TALEs could be successfully delivered and expressed by lentiviral gene transfer. Thus, it is conceivable that more suitable vectors, which are currently tested in gene-therapeutic approaches such as adenoviruses or adeno-associated viruses (Kaufmann et al., 2013) , may be applied to the TALE technology to improve in vivo purging strategies. However, as with all types of heterologous factors acting on HIV proviruses, the potential in vivo usage of TALEs faces significant technical issues such as the specific transfer to latently infected cells as well as immunological issues that need to be solved.
Conclusion
Our study suggests TALEs as an interesting tool to purge HIV gene expression. In contrast to LRAs, TALEs enable a provirusspecific, patient-adapted, induction of HIV transcription.
Materials and methods

Construction of TALEs and expression plasmids
The DNA sequences encoding the applied TALEs based on the hax3 gene of Xanthomonas campestris pv. Armoraciae. The codingunit of the Hax3 activation domain was replaced by the 68 aa VP16 domain. The genes of customized TALEs recognizing 19 nucleotides of selected regions of the HIV-1 promoter region (Fig. 1) were assembled with the 'Golden TAL Technology' (Geissler et al., 2011) . Briefly, six single-repeat modules were ligated into assembly vectors as a six-repeat array by cut-ligation using BpiI. To assemble the complete TALE-coding sequence, three six-repeat arrays were ligated with modules encoding a Flag-tag, the N-and C-terminus, and the VP16 transcription activation domain, respectively, into an expression vector pcDNA3 derivative using BsaI. The complete nucleotide sequences of all applied TALEs are given as Supplementary information. The amphotropic retroviral expression system was purchased from Cell Biolabs. The lentiviral transfer (pSH9), packaging (pMDLg/pRRE, pRSV-Rev) and envelope (pCMV-VSV-G) plasmids were described previously (Hauber et al., 2013) . The TALE-encoding retroviral and lentiviral expression vectors were generated by ligation of the respective TALE genes between the EcoRI and XhoI restriction sites of pMXs-Neo (Cell Biolabs) and pSH9, respectively. For codon-optimization of N-and C-termini and the 34 aa repeats of hax3, we applied the tool GeneOptimizer (Life Technologies) to improve the translation efficiency.
Cell culture, transfection and infection, treatment with Vorinostat
The retrovirus packaging cells Plat-A (Cell Biolabs) were grown in Dulbecco's modified Eagle's Medium (Life Technologies) supplemented with 10% FCS, 1% non-essential amino acids and 1% penicillin/streptomycin. The CD4 þ T-lymphocyte cell line 8E5 (Folks et al., 1986 ) containing a single copy of a HIV-1 proviral genome was cultured in RPMI-1640 medium (Life Technologies) supplemented with 10% FCS, 1% L-glutamine and 1% penicillin/ streptomycin. For the expression of TALEs in the 8E5 cells, the amphotropic retroviruses containing the TALE coding sequences were generated with the Platinum Retrovirus Expression System following the instructions of the manufacturer or with the lentiviral transfer and packaging system (see below). For expression via retroviruses, Plat-A cells seeded in 6-wells were transfected at 50% confluence with 4 μg TALE-encoding retroviral expression plasmid using Turbofect (ThermoScientific). The virus supernatant was harvested 48 h post transfection and tested for the recommended virus titers (Cell Biolabs). For the infection of the 8E5 cells, 20,000 cells were centrifuged at 400g and 20°C for 5 min and the cell pellet directly resuspended in 250 μl of the retrovirus-containing supernatant (MOI of 10). Following the addition of 20 μg polybrene (Millipore), the infection was performed for 90 min at 400g and 20°C. Infected 8E5 cells were cultured for 4 days. Lentiviral particles for infecting 8E5 cells or HIV-1 patient-derived PBMCs were produced by transient transfection of 5 Â 10 6 Hek293T cells with 6 μg of lentiviral transfer vector, 1.5 μg of pRSV-Rev, 1.5 μg of pCMV-VSV-G and 3 μg of pMDLg/pRRE using TransIT-LT1 (Mirus Bio LLC). At 72 h post transfection viral supernatants were collected and passed through 0.2 μm pore size filters to ensure removal of any viral aggregates. Viral particles were concentrated 50-fold by ultracentrifugation and particles were frozen at À 80°C for further use. PBMCs from two HIV-1 patients were CD8 þ T cell depleted using the Human CD8 Positive Selection Kit (StemCell) and pre-stimulated in RPMI-1640 medium (Lonza) þ10% FCS (PAN Biotech) with 1 μg/ml PHA-P, 50 ng/ml PMA and 1 μg/ml polybrene (all from Sigma-Aldrich) for 24 h. The infection of PBMCs or 8E5 cells was performed with 1 Â 10 6 cells, respectively, using a MOI of 10 for 90 min at 300g and 20°C. Thereafter, the cells were cultivated at 37°C and 5% CO 2 for 24 hours before the medium was changed and the cells were further cultured. TALE expression was measured by western blot and the transfection/transduction efficiencies were measured by co-expressed GFP (see Fig. 2 ). The PBMCs were cultured in the presence of 10 U/ml human recombinant IL-2 (Biomol). The treatment of 8E5 cells with the histone deacetylase inhibitor Vorinostat was performed with 350 nM Vorinostat (Sigma-Aldrich; dissolved in DMSO) for 24 h and DMSO as a control.
Quantitative RT-PCR and quantification of viral load titers
For the quantification of HIV-1 RNA contained in 8E5 cells, cytoplasmic RNA was extracted. For cDNA synthesis, 1 μg of RNA was heated for 5 min at 80°C and reverse transcribed by Rever-dAid H Minus Reverse Transcriptase (Fermentas) for 1 h at 42°C followed by heat inactivation for 10 min at 70°C. HIV-1 RNA in virus particles was isolated from 200 μl of 8E5 supernatant and reverse transcribed as described above. Quantitative PCRs were performed with LightCycler 480 SYBR Green I Master using a LightCycler 480 (Roche). PCR conditions were: 95°C 10 min, (95°C 5 s; 60°C 10 s; 72°C 15 s) Â 45 cycles. The qRT-PCR data were analyzed by the ΔΔCt method using GAPDH as an internal control.
For normalization of relative levels of HIV-1 RNAs in cell culture supernatants, the supernatant was supplemented with 5 fmol of Luc-polyA RNA prior to RNA extraction. The determined levels of HIV-1 RNA were correlated to this control. HIV-1 RNA expression in patient-derived CD8 þ T cell-depleted PBMCs was measured by amplification of cDNA with Platinum Quantitative PCR SuperMix-UDG/ROX Reference Dye (Life Technologies) for 40 cycles in a 7500 Fast Realtime PCR System (Applied Biosystems) at day 6 postinfection. HIV-1 RNA levels were normalized to GAPDH. Cell-free culture supernatant was assayed for viral load titer using the ultrasensitive ( o20 HIV-1 RNA copies/ml) Cobas AmpliPrep/Cobas TaqMan HIV-1 Test version 2.0 (Roche). HIV-1 p24 levels in cellfree culture supernatants of PBMCs were analyzed by HIV-1 p24 antigen ELISA (Innotest HIV p24 Antigen mAb; Innogenetics).
Patients
Patient 1 receives cART since 2001. At the time of blood draw he had constantly suppressed viremia to below 20 RNA copies/ml for more than ten years with few intermittent viral blips (o 100 RNA copies/ml). His CD4 count was 278/μl (24%). Patient 2 was diagnosed 1987. At the draw she received cART for more than ten years. The viral load was constantly suppressed; the CD4 count was 1167/μl (36%).
Characterization of activated patient PBMCs
Test for activation: The CD8-depleted patient PBMCs were stained using CD4, CD11b, CD25, CD45 and CD69 monoclonal antibodies and characterized for CD4 þ CD64 þ, CD4 þ CD25 þ, CD4 þCD11b þ cell subsets by FACS analysis using a FACSCanto II system with BD FACSDiva Software v5.0.3 and FlowJo software v7/ 9 for PC (Treestar).
Test of viral load: 10 6 CD8-depleted patient cells were incubated in 1 ml RPMI1640-medium with 10% FCS, 2 mM L-Glutamin, 0.05 mg/ml Penicillin/Streptomycin together with recombinant human IL-2 [500 U] alone or rhIL-2þPHA-P [2 mg]þPMA [1 mg] in a 24-well plate for 6 days. At day 2, 4 and 6 cell culture supernatant was analyzed for virus load using an ultrasensitive (o20 HIV-1 RNA copies/ ml) Cobas AmpliPrep/Cobas TaqMan HIV-1 Test version 2.0 assay.
Western blotting
Western blotting was performed using standard procedures. The applied antibodies were purchased from Sigma-Aldrich (vinculin, V9131; FLAG, F7425), Invitrogen (GFP, A-6455), BD Pharmingen (CD45 FITC, 555482; CD69 APC, 555533), Beckman Coulter (CD4 PE, A07751) and eBioscience (CD11b PE-Cy7, 25-0118-42; CD25 APCFluor780, 47-0259). The secondary antibodies were from GE Healthcare (anti-rabbit, NA934V; anti-mouse, NXA931).
Data evaluation/statistics
Data evaluation and statistics were done as described previously (Geissler et al., 2012) .
